Render Target: STATIC
Render Timestamp: 2024-12-12T11:19:03.001Z
Commit: 611277b6de3cd1bb065350b6ef8d63df412b7185
XML generation date: 2024-08-01 15:30:12.843
Product last modified at: 2024-09-10T20:15:07.492Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

MAGE-C2/CT10 (E7B8D) XP® Rabbit mAb #20058

Filter:
  • WB
  • IP
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 55
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100
    Immunohistochemistry (Paraffin) 1:4000 - 1:16000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #16675.

    Protocol

    Specificity / Sensitivity

    MAGE-C2/CT10 (E7B8D) XP® Rabbit mAb recognizes endogenous levels of total MAGE-C2/CT10 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val75 of human MAGE-C2/CT10 protein.

    Background

    Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).

    Melanoma-associated antigen-C2/Cancer testis antigen 10 (MAGE-C2/CT10) belongs to the type I MAGE family of proteins. In normal human tissues, MAGE-C2/CT10 expression is nuclear and largely restricted to germline cells of the testis (4). At the molecular level, research studies have demonstrated that MAGE-C2/CT10 physically interacts with and enhances activity of the TRIM28 E3 RING ubiquitin ligase (5,6). MAGE-C2/CT10 has also been shown to interact with and regulate the activity of SCF CRL E3 ubiquitin ligase complexes toward substrates that control cell cycle progression, suggesting a role for MAGE-C2/CT10 in malignant transformation (7). Indeed, MAGE-C2/CT10 is aberrantly expressed in testicular germ cell tumors, prostate carcinoma, hepatocellular carcinoma, and melanoma (8-11). Furthermore, MAGE-C2/CT10 is immunogenic in some tumor types and as a result, there is interest in targeting antigenic epitopes presented in the context of class I MHC alleles using engineered TCRs (12,13).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.